As breast cancer survival is increased by the diagnosis of earlier-stage disease and
treatments improve, the side effects of cancer treatments, such as cardiotoxicity, remain …

Curative therapy for childhood cancer has improved significantly in the last 2 decades such
that, at present,∼ 80% of all children with cancer are likely to survive≥ 5 years after …

Cardiac dysfunction resulting from exposure to cancer therapeutics was first recognized in
the 1960s, with the widespread introduction of anthracyclines into the oncological …

Background—In patients with aggressive malignancies who are undergoing high-dose
chemotherapy, even minimal elevation of troponin I (TnI) is associated with late left …

PURPOSE To determine the relative efficacy of an intensive cyclophosphamide, epirubicin,
and fluorouracil (CEF) adjuvant chemotherapy regimen compared with cyclophosphamide …

Background With increasing doses the highly tumoricidal anthracycline drugs cause heart
damage. Based on empirical drug limitations about 10–15% of patients will develop …

Background High-dose chemotherapy (HDC) has been widely utilized in high-risk breast
cancer, but it may induce cardiac toxicity. Cardiac dysfunction may become evident weeks or …

PURPOSE To evaluate the influence of cumulative dose, dose-intensity, single-dose level,
and schedule of epirubicin on the risk of develo** congestive heart failure (CHF) in …

Epirubicin is the 4′ epimer of the anthracycline antibiotic doxorubicin, and has been used
alone or in combination with other cytotoxic agents in the treatment of a variety of …

Chemotherapy-induced cardiotoxicity remains an unresolved problem strongly impacting
the quality of life and the overall survival of cancer patients. The main strategy for minimizing …